T-cell lymphoma
Clinical trials for T-cell lymphoma explained in plain language.
Never miss a new study
Get alerted when new T-cell lymphoma trials appear
Sign up with your email to follow new studies for T-cell lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can engineered cells beat relapsed blood cancers?
Cure By invitation onlyThis early-stage trial is testing an experimental cell therapy called HY035 in people with CD7-positive blood cancers that have returned or not responded to standard treatment. The goal is to see if the therapy is safe and can help achieve remission. Participants receive a single…
Matched conditions: T-CELL LYMPHOMA
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Cure
Last updated Aug 27, 2026 00:00 UTC
-
Experimental combo targets tough T-Cell lymphoma
Disease control PausedThis phase 1 trial is testing whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior treatment. Up to 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The stu…
Matched conditions: T-CELL LYMPHOMA
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for rare lymphoma: targeted drug enasidenib enters phase 2 trial
Disease control OngoingThis study tests enasidenib, a drug that targets cancer cells with a specific IDH2 mutation, in people with angioimmunoblastic T-cell lymphoma (AITL). The drug is given alone or with rituximab. The goal is to see if it safely shrinks tumors. About 25 adults whose lymphoma has ret…
Matched conditions: T-CELL LYMPHOMA
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC